Acute myeloid leukemia (AML) is an aggressive blood malignancy, characterized by the bone marrow's aberrant myeloid cells (blasts) proliferating quickly, and interfering with the body's natural ability to produce blood cells. Fatigue, frequent infections, anaemia, easy bleeding or bruises, and fever from bone marrow loss are some of the symptoms. Most AML patients are older people (median age ~69), and unchecked development and maturation arrest are caused by genetic abnormalities in myeloid precursors. The prognosis is influenced by subtypes that differ according to cytogenetic and genetic abnormalities. Chemotherapy, targeted therapy, or stem cell transplantation are the methods of treatment. Nonetheless, 5-year survival rates are still low at about 29%. Untreated AML advances quickly and frequently result in death in a matter of weeks. The acute myeloid leukemia pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the acute myeloid leukemia pipeline analysis include Bristol-Myers Squibb, AbbVie, and Actinium Pharmaceuticals, among others.
Leading drugs currently in the pipeline include CC-486, Azacitidine, and others.
Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Acute Myeloid Leukemia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acute myeloid leukemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute myeloid leukemia. The acute myeloid leukemia therapeutics report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The acute myeloid leukemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute myeloid leukemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute myeloid leukemia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Acute myeloid leukemia (AML) is caused by genetic abnormalities in hematopoietic stem cells that causes clonal proliferation and prevents myeloid precursors from differentiating. This results in Immature myeloblasts build up in the bone marrow because of these mutations (DNMT3A, TET2, etc.) that interfere with normal hematopoiesis. Class 1 encourages proliferation (like FLT3), while class 2 hinders differentiation (like NPM1), according to the "two-hit hypothesis" that explains cooperative mutations. This leads to organ infiltration and bone marrow failure (anemia, thrombocytopenia). The heterogeneity of AML results from a variety of mutational combinations that affect treatment and prognosis.
The mainstay of treatment for acute myeloid leukemia (AML) is rigorous chemotherapy, which frequently uses medications like cytarabine and anthracyclines to destroy leukemic cells. Certain genetic alterations may require the addition of targeted medicines. Consolidation therapy, either further chemotherapy or a stem cell transplant, is used to stop relapses after remission. For suitable patients, particularly those with a high risk of recurrence, stem cell transplantation, typically from a donor, is taken into consideration. In certain situations, leukapheresis or radiation therapy may also be used in addition to supportive care.
About 4.3 occurrences of acute myeloid leukemia (AML) occur per 100,000 people in the United States each year, making it a relatively uncommon malignancy. The number of new AML cases worldwide increased from 79,372 in 1990 to 144,645 in 2021, with men and older people having higher rates. People between the ages of 65 and 74 are most diagnosed with AML, and the incidence is higher in industrialized nations.
This section of the report covers the analysis of acute myeloid leukemia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, in the acute myeloid leukemia pipeline, maximum number of candidates lie in phase I with 48%, followed by phase ii with 37%. The remaining 13% of candidates are in Phase III and 2% candidates are in Phase IV. Thus, demonstrating a diverse focus toward potential treatments.
The drug molecule categories covered under the acute myeloid leukemia pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. The acute myeloid leukemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute myeloid leukemia.
The EMR report for the acute myeloid leukemia pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acute myeloid leukemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute myeloid leukemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute myeloid leukemia drug candidates.
The Bristol-Myers Squibb oral azacitidine formulation, CC-486 is presently undergoing evaluation in China as part of a Phase 2 randomized, double-blind, placebo-controlled experiment. Its effectiveness and safety as a maintenance treatment for individuals with acute myeloid leukemia (AML) in full remission after rigorous chemotherapy are evaluated in this study. The purpose of the trial is to ascertain whether CC-486, in conjunction with the finest supportive care, can extend remission and lower the risk of recurrence in comparison to supportive care alone.
AbbVie's hypomethylating drug azacitidine is being studied in a Phase 1/2 clinical trial to treat acute myeloid leukemia (AML). In this study, patients with newly diagnosed CD123-positive AML are evaluated using azacitidine in conjunction with venetoclax and pivekimab sunirine. According to preliminary results, respondents had a low residual illness negativity rate of 76% and a composite complete remission rate of 68%. These findings imply that combination therapy might present a viable alternative for AML patients seeking treatment.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Acute Myeloid Leukemia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acute myeloid leukemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into acute myeloid leukemia collaborations, regulatory environments, and potential growth opportunities.
Acute Myeloid Leukemia Treatment Market Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share